↓ Skip to main content

Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report

Overview of attention for article published in Journal of Medical Case Reports, July 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (65th percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
9 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report
Published in
Journal of Medical Case Reports, July 2014
DOI 10.1186/1752-1947-8-257
Pubmed ID
Authors

Johanna Knapstein, Marcus A Wörns, Peter R Galle, Tim Zimmermann

Abstract

Hepatitis C virus reinfection occurs universally after liver transplantation with accelerated cirrhosis rates of up to 30% within 5 years after liver transplantation. Management of hepatitis C virus reinfection is complicated by drug interactions and pre-treatment. Dual antiviral therapy with pegylated interferon and ribavirin only reaches sustained virological response rates of approximately 30% after liver transplantation. With the approval of the viral NS3/4A protease and NS5B ribonucleic acid -dependent ribonucleic acid polymerase inhibitors, combination therapy offers new therapeutic options resulting in considerably higher sustained virological response rates in the non-transplant setting. However, silibinin has also shown potent antiviral activity in non-responders to dual therapy.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 11%
Italy 1 11%
Unknown 7 78%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 22%
Student > Bachelor 2 22%
Other 1 11%
Student > Ph. D. Student 1 11%
Student > Master 1 11%
Other 1 11%
Unknown 1 11%
Readers by discipline Count As %
Medicine and Dentistry 3 33%
Social Sciences 1 11%
Chemistry 1 11%
Environmental Science 1 11%
Unknown 3 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 August 2014.
All research outputs
#6,401,099
of 12,445,728 outputs
Outputs from Journal of Medical Case Reports
#364
of 2,041 outputs
Outputs of similar age
#68,290
of 200,457 outputs
Outputs of similar age from Journal of Medical Case Reports
#2
of 2 outputs
Altmetric has tracked 12,445,728 research outputs across all sources so far. This one is in the 48th percentile – i.e., 48% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,041 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 200,457 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.